Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
21 Results for "
U2OS osteosarcoma cells
" in MedChemExpress (MCE) Product Catalog:
Products (21)
21 Results for "U2OS osteosarcoma cells" in MCE Product Catalog:
5
5 Cited Publications
Target:
Research Areas:
EN6 is a small-molecule in vivo autophagy activator that covalently targets cysteine 277 in the ATP6V1A subunit of the lysosomal v-ATPase. EN6-mediated modification of ATP6V1A uncouples v-ATPase from Rag, leading to inhibition of mTORC1 signalling, increased lysosomal acidification, and activation of autophagy. EN6 also scavenges TDP-43 aggregates (causative agents of frontotemporal dementia) in a lysosome-dependent manner .
1
1 Cited Publications
Cat. No.: HY-168438
CAS No.: 930856-19-2
Research Areas:
ERBB agonist-1 is a ERBB4 agonist with an EC50 of 10.5 μM. ERBB agonist-1 enhances NRG1-induced ERBB4 homodimerization and activates the PI3K/Akt and MAPK/ERK signaling pathways. ERBB agonist-1 acts as a cell survival promoter, anti-hypertrophic agent, anti-fibrotic agent, and cardioprotective agent. ERBB agonist-1 is applicable to the research of heart failure .
Target:
Research Areas:
JBSNF-00002 free base is an orally active small molecule inhibitor of the tricyclic nicotinamide N-methyltransferase (NNMT) with IC50 values for human, mouse and monkey sources of NNMT of 33, 210 and 190 nM respectively. JBSNF-00002 free base can reduce endogenous MNA levels in U2OS osteosarcoma cells, with its EC50 being 2.5 μM. JBSNF-00002 free base exhibits significant anti-obesity and anti-diabetic activities in the diet-induced obesity (DIO) model. JBSNF-00002 free base can be used for the study of metabolic diseases such as obesity, type 2 diabetes and non-alcoholic fatty liver disease .
Cat. No.: HY-151500B
Purity: 95.64%
Target:
Research Areas:
JBSNF-00002 hydrochloride is an orally active small molecule inhibitor of the tricyclic nicotinamide N-methyltransferase (NNMT) with IC50 values for human, mouse and monkey sources of NNMT of 33, 210 and 190 nM respectively. JBSNF-00002 hydrochloride can reduce endogenous MNA levels in U2OS osteosarcoma cells, with its EC50 being 2.5 μM. JBSNF-00002 hydrochloride exhibits significant anti-obesity and anti-diabetic activities in the diet-induced obesity (DIO) model. JBSNF-00002 hydrochloride can be used for the study of metabolic diseases such as obesity, type 2 diabetes and non-alcoholic fatty liver disease .
Cat. No.: HY-174996
CAS No.: 3031840-36-2
Target:
Research Areas:
NEP162 is a BRD4 PROTAC degrader based on the E3 ubiquitin ligase GID4, with DC50 values of 1.2 μM and 1.6 μM in SW480 and U2OS cells, respectively, and a Kd value of 0.13 µM for GID4. NEP162 bridges the E3 ligase GID4 and BRD4 to form a ternary complex, promotes polyubiquitination and subsequent degradation of BRD4 via the ubiquitin-proteasome system, reduces the proliferation capacity of tumor cells and induces apoptosis. NEP162 can be used for research on cancers such as osteosarcoma, colorectal cancer and non-small cell lung cancer .
Cat. No.: HY-P3730
CAS No.: 237392-84-6
Cat. No.: HY-151500A
Purity: 99.47%
Target:
Research Areas:
JBSNF-00002 TFA is an orally active small molecule inhibitor of the tricyclic nicotinamide N-methyltransferase (NNMT) with IC50 values for human, mouse and monkey sources of NNMT of 33, 210 and 190 nM respectively. JBSNF-00002 TFA can reduce endogenous MNA levels in U2OS osteosarcoma cells, with its EC50 being 2.5 μM. JBSNF-00002 TFA exhibits significant anti-obesity and anti-diabetic activities in the diet-induced obesity (DIO) model. JBSNF-00002 TFA can be used for the study of metabolic diseases such as obesity, type 2 diabetes and non-alcoholic fatty liver disease .
Cat. No.: HY-151500C
Target:
Research Areas:
JBSNF-00002 is an orally active small molecule inhibitor of the tricyclic nicotinamide N-methyltransferase (NNMT) with IC50 values for human, mouse and monkey sources of NNMT of 33, 210 and 190 nM respectively. JBSNF-00002 can reduce endogenous MNA levels in U2OS osteosarcoma cells, with its EC50 being 2.5 μM. JBSNF-00002 exhibits significant anti-obesity and anti-diabetic activities in the diet-induced obesity (DIO) model. JBSNF-00002 can be used for the study of metabolic diseases such as obesity, type 2 diabetes and non-alcoholic fatty liver disease .
Cat. No.: HY-P3731
CAS No.: 237392-85-7
Cdk2/Cyclin Inhibitory Peptide II (Tat-LDL), a CDK2 inhibitor, kills U2OS osteosarcoma cells in a dose-dependent manner .
Cat. No.: HY-163518
Target:
Research Areas:
Antitumor agent-153 (compound 11b) is an optimized H2A histone ubiquitination inhibitor based on PRT4165 (HY-19817). Antitumor agent-153 inhibits the viability of human osteosarcoma U2OS cells and reduces histone H2A monoubiquitination, exhibiting anticancer activity .
Cat. No.: HY-179650
CAS No.: 217798-45-3
Target:
Research Areas:
NSD2-PWWP1-IN-5 (Compound 13) is an effective NSD2-PWWP1 inhibitor with a Kd value of 78 nM. NSD2-PWWP1-IN-5 competitively blocks the recognition of H3K36me2 and DNA by NSD2-PWWP1, thereby weakening its binding ability to nucleosomes. NSD2-PWWP1-IN-5 inhibits the proliferation of U2OS osteosarcoma cells and induces cell cycle arrest and apoptosis. NSD2-PWWP1-IN-5 can be used for the study of osteosarcoma .
Cat. No.: HY-168890
CAS No.: 2486358-59-0
Target:
Research Areas:
TRF2-IN-1 (compound F2) is a potent telomere repeat-binding factor 2 (TRF2) inhibitor. TRF2-IN-1 shows antiproliferative activity. TRF2-IN-1 induces apoptosis. TRF2-IN-1 directly bind to the TRF2TRFH domain and selectively inhibits TRF2 protein expression and telomeric localization. TRF2-IN-1 shows anticancer activity. TRF2-IN-1 has the potential for the research of osteosarcoma .
Cat. No.: HY-179588
Target:
Research Areas:
PROTAC BET Degrader-14 is a highly efficient PROTAC targeting BET (bromodomain and extra-terminal domain). PROTAC BET Degrader-14 can degrade all BET (BRD2, BRD3, BRD4) family proteins. PROTAC BET Degrader-14 potently degrades BET proteins in U2OS osteosarcoma cell lines (BRD4 DC50 = 130 nM) and KYSE180 esophageal squamous cell carcinoma cell lines (DC50 = 40 nM). PROTAC BET Degrader-14’s dependence on the ubiquitin-proteasome system. PROTAC BET Degrader-14 decreases levels of BET-regulated gene products c-Myc, RUNX2, and KRT14. PROTAC BET Degrader-14 can be used for the study of osteosarcoma .
Cat. No.: HY-114322A
CAS No.: 2306193-98-4
cis-VZ185 serves as a non-degradative control and inactive analog of VZ185 (HY-114322), a dual-target BRD7/BRD9 degrader PROTAC. cis-VZ185 exerts antiproliferative activity against epithelioid sarcoma cells only at high concentrations. cis-VZ185 induces morphological changes in osteosarcoma cells. cis-VZ185 can be used in studies related to epithelioid sarcoma .
Cat. No.: HY-182746
Target:
Research Areas:
RG7388-PEG3-Click-F is a fluorinated analog of the MDM2 inhibitor RG7388 (HY-15676), with an IC50 of 16.8 nM against MDM2. [ 18F]RG7388-PEG3-Click-F exhibits high uptake and specificity in MDM2-expressing myeloma cells, and can be used for non-invasive assessment of MDM2 protein expression levels in tumors .
Cat. No.: HY-183980
Target:
Research Areas:
MJ-NR-27 is a bifunctional small molecule of ribonuclease-targeting chimera (RIBOTAC) that targets NRAS mRNA containing a G-quadruplex structure. MJ-NR-27 uses RNase L ligand 3 (HY-177030) as the RNase L ligand, RNA binder 4 (HY-183981) as the RNA binder, and Bis-PEG3-acid (HY-126891) as the linker. MJ-NR-27 achieves target RNA degradation by recruiting ribonuclease RNase L, and significantly induces morphological changes in tumor cells. MJ-NR-27 can be used in cancer research .
Cat. No.: HY-181933
CAS No.: 339025-18-2
Clathrin-IN-5 (Compound 9) is a Clathrin N-terminal domain-Amphiphysin protein-protein interaction inhibitor with an IC50 of 2.77 μM. Clathrin-IN-5 inhibits the protein-protein interaction between the clathrin N-terminal domain and amphiphysin. Clathrin-IN-5 inhibits clathrin-mediated endocytosis with an IC50 of 4.6 μM. Clathrin-IN-5 inhibits the GTPase activity of Dynamin I with an IC50 of 29.7 μM .
Cat. No.: HY-183102
CAS No.: 384860-40-6
Target:
Research Areas:
ATC12 is a Aurora-A kinase inhibitor. ATC12 binds to Aurora-A and competes with TPX2 for binding to disrupt the Aurora-A/TPX2 interaction. ATC12 inhibits cancer cell proliferation, induces apoptosis and cellular senescence. ATC12 can be used in the research of breast cancer .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
